# US 2024/0254258 A1 · Anti-alk antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254258 A1
- Document ID: US20240254258A1
- Status: Published application
- Kind: A1
- Application number: 18/545,533
- Filed: 2023-12-19
- Published: 2024-08-01
- Earliest claimed: 2021-06-28
- Assignees: Trellis Bioscience, LLC
- Applicants: Trellis Bioscience, Inc.
- Inventors: Angeles Estelles; Mikhail Gishizky; Stefan Ryser; Lawrence Kauvar
- Web page: https://patentgrep.com/patent/US20240254258A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/40: against enzymes
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 47/6817: {Toxins}
- A61K 47/6871: {the antibody targeting an enzyme}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/77: Internalization into the cell
- C12N 15/85: for animal cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are monoclonal antibodies, and antigen-binding fragments thereof, that immunospecifically bind to human Anaplastic Lymphoma Kinase (ALK). Also provided are methods of use thereof, such the treatment of cancer. Also included are antibody-drug conjugates (ADCs) including the monoclonal antibodies and/or antigen-binding fragments thereof, linked to an effector agent, such as a cytotoxic agent. Also provided are method of using such ADCs. Nucleic acid molecules, vectors, and host cells for the monoclonal antibodies and antigen-binding fragments thereof are also provided, as are pharmaceutical and veterinarian compositions including the monoclonal antibodies, and antigen-binding fragments thereof, and/or the associated ADCs.

## Claims

### Claim 1

An isolated monoclonal antibody (mAb) or antigen binding fragment thereof that specifically binds Anaplastic Lymphoma Kinase (ALK), the mAb or antigen binding fragment thereof comprising a heavy chain variable region (VH) as set forth in the amino acid sequence corresponding to SEQ ID NO:1 and a light chain variable (VL) region as set forth in the amino acid sequence corresponding SEQ ID NO: 8.

### Claim 2 (depends on 1)

The isolated mAb or antigen binding fragment thereof of claim 1, wherein the mAb or antigen binding fragment thereof is monospecific, bispecific, or multispecific.

### Claim 3 (depends on 1)

The isolated mAb or antigen binding fragment thereof of claim 1, wherein the mAb or antigen binding fragment thereof is a chimeric antibody or chimeric antigen binding fragment thereof, a human antibody or human antigen binding fragment thereof, a humanized antibody or humanized antigen binding fragment thereof, or a single chain antibody.

### Claim 4 (depends on 1)

The isolated mAb or antigen binding fragment thereof of claim 1, wherein the mAb is a complete antibody.

### Claim 5 (depends on 1)

The isolated mAb or antigen binding fragment thereof of claim 1, wherein the antigen binding fragment comprises a fragment selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment, an F(ab′)2 fragment, a single-chain Fv (scFV) fragment, and a single-chain Fab (scFab) fragment.

### Claim at position 6

-9. (canceled)

### Claim 10 (depends on 1)

A pharmaceutical or veterinary composition, the composition comprising the isolated mAb or antigen binding fragment thereof of claim 1.

### Claim 11 (depends on 1)

An isolated nucleic acid that encodes, or a plurality of isolated nucleic acids that separately or in combination encodes, the variable light chain and the variable heavy chain regions of the mAb or antigen binding fragment thereof of claim 1.

### Claim 12 (depends on 11)

A vector comprising the isolated nucleic acid or plurality of isolated nucleic acids of claim 11.

### Claim 13 (depends on 12)

An isolated cell comprising the vector according to claim 12.

### Claim 14 (depends on 1)

A method of targeting a cancer cell, comprising administering the mAb or antigen binding fragment of claim 1 to a subject.

### Claim at position 12

-22. (canceled)

### Claim 23

An isolated monoclonal antibody (mAb) or antigen binding fragment thereof that specifically binds Anaplastic Lymphoma Kinase (ALK), the isolated mAb or antigen binding fragment thereof comprising heavy chain variable region and a light chain variable region, wherein
(a) the heavy chain variable region comprises complementarity determining regions CDR-H1 (SEQ ID NO: 2), CDR-H2 (SEQ ID NO: 3), and CDR-H3 (SEQ ID NO: 4) and the light chain variable region comprises CDR-L1 (SEQ ID NO: 9), CDR-L2 (SEQ ID NO: 10), and CDR-L3 (SEQ ID NO: 11), or wherein
(b) the heavy chain variable region comprises complementarity determining regions CDR-H1 (SEQ ID NO: 5), CDR-H2 (SEQ ID NO: 6), and CDR-H3 (SEQ ID NO: 7) and the light chain variable region comprises CDR-L1 (SEQ ID NO: 12), CDR-L2 (SEQ ID NO: 13), and CDR-L3 (SEQ ID NO: 14).

### Claim 24

(canceled)

### Claim 25 (depends on 23)

The isolated mAb or antigen binding fragment thereof of claim 23, wherein the mAb or antigen binding fragment thereof is a chimeric antibody or chimeric antigen binding fragment thereof, a human antibody or human antigen binding fragment thereof, a humanized antibody or humanized antigen binding fragment thereof, or a single chain antibody.

### Claim at position 16

-29. (canceled)

### Claim 30 (depends on 23)

An immunoconjugate comprising (a) the isolated mAb or antigen binding fragment thereof of claim 23 and (b) an effector agent selected from the group comprising a toxin and a radioligand.

### Claim at position 18

-32. (canceled)

### Claim 33 (depends on 23)

An isolated nucleic acid that encodes, or a plurality of isolated nucleic acids that separately or in combination encode, the variable light chain and the variable heavy chain regions of the isolated mAb or antigen binding fragment thereof of claim 23.

### Claim at position 20

-35. (canceled)

### Claim 36 (depends on 23)

A method of treating cancer in a subject, the method comprising administering to the subject the isolated mAb or antigen binding fragment thereof of claim 23.

### Claim 37

An isolated nucleic acid, or a plurality of isolated nucleic acids, wherein the isolated nucleic acid comprises, or the plurality of isolated nucleic acids comprise, a sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleic acid sequence set forth in SEQ ID NOS: 15, 22, 30, 32, 34, 36, 38, 40, 42, or 44.

### Claim 38

(canceled)

### Claim 39 (depends on 37)

The isolated nucleic acid, or the plurality of isolated nucleic acids, of claim 37 wherein the isolated nucleic acid comprises, or the plurality of isolated nucleic acids comprise, the nucleic acid sequence set forth in SEQ ID NOS: 16, 17, and 18 or SEQ ID NOS: 23, 24, and 25.

### Claim 40 (depends on 33)

A method of treating cancer, the method comprising administering to a subject one or more of the isolated nucleic acids set forth in claim 33.

### Claim 41

A method of treating cancer, the method comprising administering to a subject any one or more nucleic acid sequences that encode the amino acid sequence set forth as SEQ ID NOS: 1-14, 29, 31, 33, 35, 37, 39, 41, or 43.

### Claim 42

(canceled)

### Claim 43 (depends on 42)

The method of claim 42, wherein nucleic acid is complexed with a lipid nanoparticle (LNP).
